364 related articles for article (PubMed ID: 25044088)
21. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K
Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884
[TBL] [Abstract][Full Text] [Related]
22. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
23. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
24. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
25. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
26. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
27. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
28. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683
[TBL] [Abstract][Full Text] [Related]
29. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E
Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653
[TBL] [Abstract][Full Text] [Related]
30. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.
Ansell SM
Am J Hematol; 2016 Jan; 91(1):109-12. PubMed ID: 26505486
[TBL] [Abstract][Full Text] [Related]
31. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
32. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
Filatova LV; Plotnikova AA; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2013; 59(2):59-65. PubMed ID: 23814851
[TBL] [Abstract][Full Text] [Related]
33. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
[TBL] [Abstract][Full Text] [Related]
34. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
35. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
Ann Oncol; 2008 Oct; 19(10):1795-801. PubMed ID: 18544558
[TBL] [Abstract][Full Text] [Related]
36. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
37. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
Diehl V
J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
[No Abstract] [Full Text] [Related]
38. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Koontz MZ; Horning SJ; Balise R; Greenberg PL; Rosenberg SA; Hoppe RT; Advani RH
J Clin Oncol; 2013 Feb; 31(5):592-8. PubMed ID: 23295809
[TBL] [Abstract][Full Text] [Related]
39. Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse).
Ansell SM
Hematol Oncol Clin North Am; 2014 Feb; 28(1):75-86. PubMed ID: 24287069
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.
Elbl L; Vasova I; Kral Z; Tomaskova I; Smardova L; Wagnerova B; Jedlicka F; Vorlicek J
J Chemother; 2006 Apr; 18(2):199-208. PubMed ID: 16736890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
